The global Low Molecular Weight Heparin Market was valued at 3.8 billion in 2022 and it is anticipated to grow up to USD 8.5 billion by 2032, at a CAGR of 8.4% during the forecast period.
Low molecular weight heparin (LMWH) is a class of anticoagulants. They are used to treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and myocardial infarction, and prevent blood clots. Low molecular weight heparin offers more advantages than heparin as it has better bioavailability, longer half-life, simplified dosing, predictable anticoagulant response, lower HIT risk, and lower osteoporosis risk.
To Remain ‘Ahead’ Of Your Competitors, Request for A Sample – https://www.globalinsightservices.com/request-sample/GIS10497
LMWH can be administered subcutaneously once or twice daily without coagulation monitoring, even when the drug is administered in treatment doses. Most patients do not require coagulation monitoring with LMWH. The effects of unfractionated heparin (UFH) or standard heparin vary from patient to patient. Therefore, it can only be administered to hospitalized patients under supervision. In addition, the LMWH has more predictable pharmacokinetic properties than unfractionated heparin, which allows its administration in fixed doses based on laboratory monitoring, without the need for dose adjustments.
Market Trends and Drivers
Developments by Companies to Drive Low Molecular Weight Heparin Market:
The Shenzhen Panorama Network has increased the production of new LMWH products to expand its presence in the market. In May 2020, Meitheal Pharmaceuticals Inc. received an FDA approval for Enoxaparin Sodium Injection (USP), a generic equivalent of Lovenox. The increasing propensity of research institutes to encourage the use of LMWH in new treatments would boost its demand in the future. The LMWH helps improve coagulation disorder occurring in COVID-19 patients; it exerts anti-inflammatory effects by reducing IL-6 and stimulating lymphocyte percentage. This application of LMWH is paving the way for well-controlled clinical trials in the field of COVID-19.
The American University of Beirut Medical Center is sponsoring a study of bemiparin sodium (a form of LMWH), which is in Phase IV clinical trials that are being conducted for its ability to improve pregnancy outcomes in patients with recurrent implantation failure, who are undergoing IVF/ICSI treatment. In addition, important players in the market are working with hospitals to strengthen their product portfolio. For example, Bayer is working with Assistance Publique – Hopitaux de Paris to investigate the combination of rivaroxaban and low molecular weight heparin against neoplasms and venous thromboembolism, which is in the Phase 3 trial.
Major Players in the Global Low Molecular Weight Heparin Market
Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Low Molecular Weight Heparin market include Aspen Holdings, Changzhou Qianhong Bio-pharma, LEOPHARMA A/S, Teva Pharmaceutical Industries Ltd., B. Braun Medical Inc., Pfizer Inc., Sanofi-Aventis, Dr. Reddy’s Laboratories Limited, and Abbott among others.
COVID-19 Impact
The spread of the COVID-19 pandemic has emphasized health data sharing and interoperability under the microscope. The infection of novel coronavirus in children is mild compared to adults, and children are assigned a better prognosis. The interruptions in the supply chain and the massive demand for efficient treatments for COVID-19 have put the health research industry in Asia-Pacific in a crucial position.
Get Customized Report as Per Your Requirement – https://www.globalinsightservices.com/request-customization/GIS10497
Global Low Molecular Weight Heparin Market Segmentation
By Drug Type
- Enoxaparin
- Dalteparin
- Nadroparin
- Bemiparin
- Tinzaparin
- Others
Buy Now – https://www.globalinsightservices.com/checkout/single_user/GIS10497
By Packaging
- Multi-vials
- Prefilled Syringes
By Application
- Deep Vein Thrombosis
- Acute Coronary Syndrome (ACS)
- Pulmonary Embolism
- Atrial Fibrillation
By End-user
- Hospitals
- Clinics
- Ambulatory Surgical Centers
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
New Report Published by Global Insight Services: https://www.globalinsightservices.com/reports/hydrogen-projects-database/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700
Website: https://www.globalinsightservices.com/